ArticlePituitary2013
Pegvisomant and cabergoline combination therapy in acromegaly.
Article in Pituitary, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 64 citations in OpenAlex.
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- Current treatment landscape of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Medical treatment of functional pituitary adenomas, trials and tribulations.Journal of neuro-oncology · 2024Review
- Multidisciplinary management of acromegaly: A consensus.Reviews in endocrine & metabolic disorders · 2020Review
- Novel therapies for acromegaly.Endocrine connections · 2020Review
- Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020Review
- The causes and consequences of pituitary gigantism.Nature reviews. Endocrinology · 2018Review
- Review
- Dopamine Agonists for Pituitary Adenomas.Frontiers in endocrinology · 2018Review
- Cabergoline in acromegaly.Pituitary · 2017Review
- Review
- Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.Pituitary · 2015Article
- Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.Journal of endocrinological investigation · 2015Article
- Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.Journal of endocrinological investigation · 2014Article
- Cabergoline treatment in acromegaly: cons.Endocrine · 2014Article
- Cabergoline treatment in acromegaly: pros.Endocrine · 2014Article
- Article
- The position of combined medical treatment in acromegaly.Archives of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination with cabergoline may offer additional benefits to acromegalic patients on pegvisomant monotherapy. We evaluated the safety and efficacy profile of this combination and investigated the determinants of response. An observational, retrospective, cross-sectional study. Fourteen acromegalic patients (9 females), who were partially resistant to somatostatin analogs and on pegvisomant monotherapy. Cabergoline was added because of the presence of persistent mildly increased IGF-I. The mean follow-up time was 18.3 ± 10.4 months. The efficacy and safety profile was assessed. The influence of clinical and biochemical characteristics on treatment efficacy was studied. IGF-I levels returned to normal in 4 patients (28%) at the end of the study. In addition, some decline in IGF-I levels was observed in a further 5 patients. The % IGF-I decreased from 158 ± 64% to 124 ± 44% (p = 0.001). The average change in IGF-I was -18 ± 27% (range -67 to +24%). Lower baseline IGF-I (p = 0.007), female gender (p = 0.013), lower body weight (p = 0.031), and higher prolactin (PRL) levels (p = 0.007) were associated with a better response to combination therapy. There were no significant severe adverse events. Significant tumour shrinkage was observed in 1 patient. Combination therapy with pegvisomant and cabergoline could provide better control of IGF-I in some patients with acromegaly. Baseline IGF-I levels, female gender, body weight, and PRL levels affect the response to this combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.